Authors' objectives:

This report provides a systematic review of the scientific evidence to answer three questions of whether short stature in a child 1) due to a medically determinable cause or 2) due to skeletal dysplasia may be associated with disability, and 3) whether decreasing growth velocity in a child with a chronic disease may serve as an indicator of severity of the disease.

Authors' results and conclusions: Based on the reviewed articles, no severe functional limitations were found in children with short stature due to isolated short stature, growth hormone deficiency, multiple hormone deficiency, Turner syndrome, or Russell-Silver syndrome. The studies reviewed focused on intelligence, academic achievement, behavior, visual-motor perception, and psychomotor development. In each of these categories, children with short stature either had testing that was not significantly different from the controls or from the population mean, or if the testing were significantly poorer, it was generally within 1 standard deviation (SD) of the population mean. Based on the articles reviewed, children with skeletal dysplasias were not at increased risk of having severe impairments in intelligence, academic achievement, or psychological outcome. There was an increased risk for delay in achievement of motor skills in children with achondroplasia and osteogenesis imperfecta, and decreased ambulation, range of motion and mobility in children with more severe forms of osteogenesis imperfecta. The results for hearing impairment, respiratory dysfunction and spinal curvature appear to indicate an increased risk for impairment in these three areas, but the studies were limited in the number of children evaluated and how the samples were selected. The evidence from four conditions (congenital heart disease, juvenile rheumatoid arthritis, Crohn's disease and human immunodeficiency virus (HIV) infection) appear to indicate that a sustained decrease in linear growth velocity can be used as a marker of the severity of these underlying conditions. Evidence is less clear for asthma, atopic dermatitis, diabetes, beta-thalassemia, and chronic kidney disease. There was only one study each for sickle cell disease, congenital adrenal hyperplasia and cerebral palsy so it is difficult to draw conclusions for these conditions. No study addressed whether the process of having a decreasing height velocity was likely to be disabling.

Authors' recommendations: No severe functional limitations were found in children with short stature due to growth hormone deficiency, multi-hormone deficiency, Turner syndrome, Russell-Silver syndrome or isolated short stature. These children generally scored within 1 SD of the population mean. Children with skeletal dysplasias were not at increased risk of having severe impairments in intelligence, academic achievement, or psychological outcome. Sustained decrease in linear growth velocity has been shown to be associated with the severity of congenital heart disease, juvenile rheumatoid arthritis, Crohn's disease, and HIV.

Authors' methods: Systematic review

Project Status: Completed

URL for project: http://www.ahrq.gov/downloads/pub/evidence/pdf/short/short.pdf

Year Published: 2003

URL for published report: http://www.ahrq.gov/clinic/epcsums/shortsum.htm

English language abstract: An English language summary is available

Publication Type: Not Assigned

Country: United States

Organisation Name: Agency for Healthcare Research and Quality

Contact Address: Center for Outcomes and Evidence Technology Assessment Program, 540 Gaither Road, Rockville, MD 20850, USA. Tel: +1 301 427 1610; Fax: +1 301 427 1639;

Contact Name: martin.erlichman@ahrq.hhs.gov

Contact Email: martin.erlichman@ahrq.hhs.gov

Copyright: Agency for Healthcare Research and Quality (AHRQ)